Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EG-MCV4 immunogenicity and safety in healthy adults
NCT07204457Phase 3Recruiting
- Sponsor
- EyeGene, Inc.
- Start
- Oct 2025
- Primary completion
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of EG-MCV4 in meningococcal infection, sponsored by EyeGene, Inc.. Started Oct 2025; status: recruiting.
02
Drugs
EG-MCV4
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT07204457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07204457.